KR102666879B1 - 항-tslp 항체를 이용한 천식의 치료 - Google Patents

항-tslp 항체를 이용한 천식의 치료 Download PDF

Info

Publication number
KR102666879B1
KR102666879B1 KR1020197033043A KR20197033043A KR102666879B1 KR 102666879 B1 KR102666879 B1 KR 102666879B1 KR 1020197033043 A KR1020197033043 A KR 1020197033043A KR 20197033043 A KR20197033043 A KR 20197033043A KR 102666879 B1 KR102666879 B1 KR 102666879B1
Authority
KR
South Korea
Prior art keywords
seq
antibody
amino acid
set forth
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197033043A
Other languages
English (en)
Korean (ko)
Other versions
KR20190140956A (ko
Inventor
제인 알. 파르네스
자넷 그리피스
Original Assignee
암젠 인크
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인크, 메디뮨 엘엘씨 filed Critical 암젠 인크
Priority to KR1020247015858A priority Critical patent/KR20240070727A/ko
Publication of KR20190140956A publication Critical patent/KR20190140956A/ko
Application granted granted Critical
Publication of KR102666879B1 publication Critical patent/KR102666879B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020197033043A 2017-04-12 2018-04-12 항-tslp 항체를 이용한 천식의 치료 Active KR102666879B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247015858A KR20240070727A (ko) 2017-04-12 2018-04-12 항-tslp 항체를 이용한 천식의 치료

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US62/484,864 2017-04-12
US201762553477P 2017-09-01 2017-09-01
US201762553575P 2017-09-01 2017-09-01
US62/553,477 2017-09-01
US62/553,575 2017-09-01
PCT/US2018/027271 WO2018191479A1 (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247015858A Division KR20240070727A (ko) 2017-04-12 2018-04-12 항-tslp 항체를 이용한 천식의 치료

Publications (2)

Publication Number Publication Date
KR20190140956A KR20190140956A (ko) 2019-12-20
KR102666879B1 true KR102666879B1 (ko) 2024-05-23

Family

ID=62092313

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197033043A Active KR102666879B1 (ko) 2017-04-12 2018-04-12 항-tslp 항체를 이용한 천식의 치료
KR1020247015858A Pending KR20240070727A (ko) 2017-04-12 2018-04-12 항-tslp 항체를 이용한 천식의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247015858A Pending KR20240070727A (ko) 2017-04-12 2018-04-12 항-tslp 항체를 이용한 천식의 치료

Country Status (22)

Country Link
US (3) US10828365B2 (https=)
EP (1) EP3609917A1 (https=)
JP (4) JP7330896B2 (https=)
KR (2) KR102666879B1 (https=)
CN (1) CN110573525A (https=)
AU (2) AU2018253118B2 (https=)
BR (1) BR112019021482A2 (https=)
CA (1) CA3059364A1 (https=)
CL (1) CL2019002897A1 (https=)
CO (1) CO2019011462A2 (https=)
IL (1) IL269791B (https=)
JO (1) JOP20190243B1 (https=)
MX (1) MX2019012158A (https=)
MY (1) MY207509A (https=)
PE (1) PE20200484A1 (https=)
PH (1) PH12019502331A1 (https=)
SG (1) SG11201909322VA (https=)
TN (1) TN2019000289A1 (https=)
TW (2) TW202523688A (https=)
UA (1) UA130334C2 (https=)
UY (1) UY37676A (https=)
WO (1) WO2018191479A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210650T1 (hr) * 2015-09-09 2021-05-28 Novartis Ag Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
JP7628966B2 (ja) 2019-06-04 2025-02-12 ジエンス ヘンルイ メデイシンカンパニー リミテッド 胸線間質性リンパ球増殖因子に結合可能な抗体およびその使用
CA3147044A1 (en) * 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
EP4025602A4 (en) * 2019-09-04 2023-12-13 Biosion, Inc. TSLP BINDING ANTIBODIES AND USES THEREOF
PH12022551022A1 (en) * 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
CN114887053B (zh) * 2019-11-29 2026-04-24 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
AU2020400221A1 (en) * 2019-12-13 2022-05-19 Harbour Biomed (Shanghai) Co., Ltd. Anti-TSLP antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4103605A1 (en) * 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
MX2022010012A (es) * 2020-02-13 2022-09-07 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria.
IL295511A (en) * 2020-02-18 2022-10-01 Amgen Inc Formulations of human anti-tslp antibodies and methods of using them
CN113388035B (zh) * 2020-03-13 2026-02-27 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
EP4302778A4 (en) * 2021-03-03 2025-03-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING AN ANTI-TSLP ANTIBODY
PH12023552762A1 (en) * 2021-04-19 2024-04-15 Medimmune Ltd An anti-tslp fab with improved stability
KR20230175245A (ko) 2021-04-23 2023-12-29 암젠 인크 변형된 항-tslp 항체
EP4326766A1 (en) * 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CN113683694B (zh) * 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗ｔｓｌｐ抗體組成物及其用途
WO2025049343A1 (en) * 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-tslp antibody constructs and uses thereof
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
US20260098100A1 (en) * 2024-10-04 2026-04-09 Prana Therapies, Inc. Il-4r and tslp inhibitors and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
ES2784123T3 (es) 2009-11-04 2020-09-22 Merck Sharp & Dohme Anticuerpo anti TSLP genomodificado
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
AR098155A1 (es) * 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
CA2955086A1 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR20170123315A (ko) * 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEW ENGLAND JOURNAL OF MEDICINE(2014), vol.370, no.22, pp2102-2110(2014.05.24.) 1부.*

Also Published As

Publication number Publication date
CA3059364A1 (en) 2018-10-18
AU2018253118B2 (en) 2025-04-10
CO2019011462A2 (es) 2019-10-31
JP2025170430A (ja) 2025-11-18
IL269791A (en) 2019-11-28
WO2018191479A1 (en) 2018-10-18
MY207509A (en) 2025-02-28
TW201838652A (zh) 2018-11-01
US20210052726A1 (en) 2021-02-25
CL2019002897A1 (es) 2020-03-06
BR112019021482A2 (pt) 2020-05-12
US20250032608A1 (en) 2025-01-30
AU2018253118A1 (en) 2019-10-24
KR20240070727A (ko) 2024-05-21
AU2025204735A1 (en) 2025-07-17
JP2023099233A (ja) 2023-07-11
KR20190140956A (ko) 2019-12-20
JP7330896B2 (ja) 2023-08-22
SG11201909322VA (en) 2019-11-28
JOP20190243A1 (ar) 2019-10-13
JP2020516647A (ja) 2020-06-11
TN2019000289A1 (en) 2021-05-07
PE20200484A1 (es) 2020-03-03
US10828365B2 (en) 2020-11-10
JP2024150751A (ja) 2024-10-23
IL269791B (en) 2022-07-01
US20180296669A1 (en) 2018-10-18
JOP20190243B1 (ar) 2024-12-22
PH12019502331A1 (en) 2020-09-28
MX2019012158A (es) 2019-12-16
UY37676A (es) 2018-10-31
TW202523688A (zh) 2025-06-16
EP3609917A1 (en) 2020-02-19
UA130334C2 (uk) 2026-01-28
CN110573525A (zh) 2019-12-13
TWI856945B (zh) 2024-10-01

Similar Documents

Publication Publication Date Title
KR102666879B1 (ko) 항-tslp 항체를 이용한 천식의 치료
KR20230175245A (ko) 변형된 항-tslp 항체
KR20220143699A (ko) 인간 항-tslp 항체 제형 및 이의 이용 방법
US20230073888A1 (en) Treatment of atopic dermatitis with anti-tslp antibody
IL302445A (en) Use of an IL-18 antagonist for the treatment and/or prevention of atopic dermatitis or a related condition
KR20260013478A (ko) 항-tslp 항체를 사용한 코르티코스테로이드 의존성 천식의 치료
KR20250140101A (ko) 항-tslp 항체를 이용한 만성 비부비동염의 치료
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
WO2025221247A1 (en) Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2025120567A1 (en) Method of treatment of asthma
US20140248289A1 (en) Methods and Compositions for the Treatment of Respiratory Conditions Via NKG2D Inhibition

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210412

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230227

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230821

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230227

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230821

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230427

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210412

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240207

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20240122

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230821

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230427

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210412

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240513

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240513

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240514

End annual number: 3

Start annual number: 1

PG1601 Publication of registration